In this case study for CNS, we present the power of PharmScreen to explore a dataset of compounds selected among inhibitors of Soluble Epoxide Hydrolase, a new target for relevant therapeutic strategy in Alzheimer Disease (AD). When dealing with CNS drug design, it is often difficult to rely on computational techniques in the early stages of drug discovery. Although the absence of defined target structures in protein misfolded related diseases (such as Parkinson and AD) is not a problem due to the ligand-based nature of PharmScreen ®.